Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy

Overview

Journal Crohns Colitis 360

Publisher Oxford University Press

Date 2023 Feb 13

PMID 36777748

Authors

Ajit Sood

Arshdeep Singh

Vandana Midha

Ramit Mahajan

Dina Kao

David T Rubin

Charles N Bernstein

Affiliations

Soon will be listed here.

Abstract

Background: Fecal microbiota transplantation (FMT) is currently an approved treatment for recurrent and refractory Clostridioides difficile infection. However, its use in ulcerative colitis is at an early stage and significant gaps remain in our understanding of the mechanisms and logistics of its practical application.

Methods And Results: This article aims to look into specific issues which remain unsettled for use of FMT in ulcerative colitis including donor and recipient selection, route of administration, and duration of therapy. We also discuss optimal ways to assess response to FMT and the current state of FMT regulations. In addition, we postulate the impact of diet on the microbiome profile of the donor and recipient. We also suggest a change in the nomenclature from FMT to fecal microbiome transfer.

Conclusion: FMT is an evolving therapy. There are several considerations for its use in UC but its use and role should be directed by further clinical trials.

Citing Articles

A practical approach to positioning therapies in ulcerative colitis.

Yanofsky R, Rubin D J Can Assoc Gastroenterol. 2025; 8(Suppl 2):S6-S14.

PMID: 39990515 PMC: 11842905. DOI: 10.1093/jcag/gwae058.

Current Pharmacologic Options and Emerging Therapeutic Approaches for the Management of Ulcerative Colitis: A Narrative Review.

Sebastian S, Kaiwan O, Co E, Mehendale M, Mohan B Spartan Med Res J. 2024; 9(3):123397.

PMID: 39280117 PMC: 11402463. DOI: 10.51894/001c.123397.

Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease.

Boicean A, Bratu D, Fleaca S, Vasile G, Shelly L, Birsan S Pathogens. 2023; 12(9).

PMID: 37764957 PMC: 10535282. DOI: 10.3390/pathogens12091149.

The Role of the Human Gut Microbiome in Inflammatory Bowel Disease and Radiation Enteropathy.

Fernandes D, Andreyev J Microorganisms. 2022; 10(8).

PMID: 36014031 PMC: 9415405. DOI: 10.3390/microorganisms10081613.

Fecal Microbiota Transplantation Donor and Dietary Fiber Intervention Collectively Contribute to Gut Health in a Mouse Model.

Zhong Y, Cao J, Ma Y, Zhang Y, Liu J, Wang H Front Immunol. 2022; 13:842669.

PMID: 35185934 PMC: 8852624. DOI: 10.3389/fimmu.2022.842669.

References

Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R . European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017; 66(4):569-580. PMC: 5529972. DOI: 10.1136/gutjnl-2016-313017. View

Ellermann M, Arthur J . Siderophore-mediated iron acquisition and modulation of host-bacterial interactions. Free Radic Biol Med. 2016; 105:68-78. PMC: 5401654. DOI: 10.1016/j.freeradbiomed.2016.10.489. View

Kelly C, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A . Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015; 149(1):223-37. PMC: 4755303. DOI: 10.1053/j.gastro.2015.05.008. View

Francino M . Early development of the gut microbiota and immune health. Pathogens. 2014; 3(3):769-90. PMC: 4243441. DOI: 10.3390/pathogens3030769. View

Papanicolas L, Choo J, Wang Y, Leong L, Costello S, Gordon D . Bacterial viability in faecal transplants: Which bacteria survive?. EBioMedicine. 2019; 41:509-516. PMC: 6444077. DOI: 10.1016/j.ebiom.2019.02.023. View

Imdad A, Nicholson M, Tanner-Smith E, Zackular J, Gomez-Duarte O, Beaulieu D . Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2018; 11:CD012774. PMC: 6517295. DOI: 10.1002/14651858.CD012774.pub2. View

Staley C, Kaiser T, Vaughn B, Graiziger C, Hamilton M, Kabage A . Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection. mBio. 2019; 10(4). PMC: 6650559. DOI: 10.1128/mBio.01586-19. View

Borody T, George L, Andrews P, Brandl S, Noonan S, Cole P . Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?. Med J Aust. 1989; 150(10):604. DOI: 10.5694/j.1326-5377.1989.tb136704.x. View

Fuentes S, Rossen N, van der Spek M, Hartman J, Huuskonen L, Korpela K . Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME J. 2017; 11(8):1877-1889. PMC: 5520032. DOI: 10.1038/ismej.2017.44. View

10.

Glover L, Lee J, Colgan S . Oxygen metabolism and barrier regulation in the intestinal mucosa. J Clin Invest. 2016; 126(10):3680-3688. PMC: 5096807. DOI: 10.1172/JCI84429. View

11.

He Z, Li P, Zhu J, Cui B, Xu L, Xiang J . Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. Sci Rep. 2017; 7(1):4753. PMC: 5500501. DOI: 10.1038/s41598-017-04984-z. View

12.

Costello S, Hughes P, Waters O, Bryant R, Vincent A, Blatchford P . Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. JAMA. 2019; 321(2):156-164. PMC: 6439766. DOI: 10.1001/jama.2018.20046. View

13.

Rossen N, Fuentes S, van der Spek M, Tijssen J, Hartman J, Duflou A . Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015; 149(1):110-118.e4. DOI: 10.1053/j.gastro.2015.03.045. View

14.

Ng S, Chan F, Chan P . Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification. Lancet Gastroenterol Hepatol. 2020; 5(7):642-643. PMC: 7176392. DOI: 10.1016/S2468-1253(20)30124-2. View

15.

Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X . Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020; 5(5):434-435. PMC: 7158584. DOI: 10.1016/S2468-1253(20)30083-2. View

16.

Hooper L, Macpherson A . Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010; 10(3):159-69. DOI: 10.1038/nri2710. View

17.

Damman C, Miller S, Surawicz C, Zisman T . The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?. Am J Gastroenterol. 2012; 107(10):1452-9. DOI: 10.1038/ajg.2012.93. View

18.

Hui W, Li T, Liu W, Zhou C, Gao F . Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS One. 2019; 14(1):e0210016. PMC: 6343888. DOI: 10.1371/journal.pone.0210016. View

19.

Costello S, Conlon M, Vuaran M, Roberts-Thomson I, Andrews J . Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 2015; 42(8):1011-8. DOI: 10.1111/apt.13366. View

20.

Ott S, Musfeldt M, Timmis K, Hampe J, Wenderoth D, Schreiber S . In vitro alterations of intestinal bacterial microbiota in fecal samples during storage. Diagn Microbiol Infect Dis. 2004; 50(4):237-45. DOI: 10.1016/j.diagmicrobio.2004.08.012. View